Who is eligible for clinical trial NCT05061134?

Participants must meet protocol criteria for Melanoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05061134 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-07-21

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition (NCT05061134)

A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 Inhibition

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.

Who can join: Review the eligibility criteria below.

Location: Research Site — Los Angeles, California

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (66 Sites)

Showing the first 25 of 66 sites.

Research Site — Los Angeles, California
Research Site — Sacramento, California
Research Site — San Francisco, California
Research Site — Tampa, Florida
Research Site — Lutherville-Timonium, Maryland
Research Site — Nashville, Tennessee
Research Site — Darlinghurst,
Research Site — East Melbourne,
Research Site — Herston,
Research Site — Woolloongabba,
Research Site — Belgium,
Research Site — Bruges,
Research Site — Ghent,
Research Site — Leuven,
Research Site — Edmonton, Alberta
Research Site — Toronto, Ontario
Research Site — Toronto, Ontario
Research Site — Ste-Foy, Quebec
Research Site — Bobigny,
Research Site — Boulogne-Billancourt,
Research Site — Marseille,
Research Site — Paris,
Research Site — Pau,
Research Site — Pierre-Bénite,
Research Site — Poitiers,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Melanoma

Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida

Explore by condition: All Melanoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗